By Najat KantouarIndivior said it has reached an agreement with Actavis Laboratories UT to resolve patent disputes regarding Actavis's Abbreviated New Drug Application for generic buprenorphine and naloxone sublingual film. The U.K.-listed pharmaceutical company said Wednesday that under the agreement, Indivior granted Actavis a license to a U.S. patent. This would enable Actavis to launch the generic film products in the U.S. no earlier than Jan. 31, 2025, "unless the unexpired patent claims are found invalid or unenforceable before that time in a final judicial decision". Write to Najat Kantouar at najat.kantouar@wsj.com

Source: Wall Street Journal December 20, 2023 18:23 UTC